Over the last decade, based on evidence from multiple randomized clinical trials, transcatheter aortic valve replacement (TAVR) has become the established treatment for patients with symptomatic severe aortic stenosis (AS). Despite the overwhelming expansion of TAVR in Western countries, initial uptake and widespread adoption of this procedure has been relatively delayed in Asian countries, owing to the high cost of devices, limited local health and reimbursement policies, and lack of specific training/proctoring program, specialized heart team, or dedicated infrastructure. Furthermore, it has not yet been determined whether there are substantial inter-racial and ethnic differences in clinical characteristics, comorbidities, and anatomic features, as well as procedural and long-term outcomes, in patients receiving TAVR. In this review, we provide not only a comprehensive look at the current status and outcomes of TAVR in Asian populations, compared with those of Western populations, but also the future perspective of TAVR in Asia.
JACC: Asia Editor-in-Chief
Jian’an Wang, MD, PhD, FACC
CME Editor
Kenneth A. Ellenbogen, MD
Authors
Cheol Hyun Lee, MD, PhD
Taku Inohara, MD, PhH
Kentaro Hayashida, MD, PhD
Duk-Woo Park, MD, PhD
Important Dates
Date of Release: December 21, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: December 20, 2022